The absolute bioavailability of oral vinorelbine in patients with solid tumors

[1]  David Khayat,et al.  Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design , 2004, Cancer Chemotherapy and Pharmacology.

[2]  R. Gascoyne,et al.  Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy , 2003 .

[3]  T. Delozier,et al.  Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Gridelli,et al.  Pharmacokinetics of Navelbine® Oral in Elderly Patients , 2002, Tumori.

[5]  M. Piccart,et al.  Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  E. Lemarié,et al.  Oral vinorelbine: feasibility and safety profile. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Fumoleau,et al.  Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  E. Lemarié,et al.  A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  E. Bajetta,et al.  Single-Agent Chemotherapy with Vinorelbine for Pretreated or Metastatic Squamous Cell Carcinoma of the Esophagus , 2001, Tumori.

[10]  C. Puozzo,et al.  New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. , 2001, Journal of chromatography. A.

[11]  A. Jakobsen,et al.  Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. , 2001, Gynecologic oncology.

[12]  M. Airoldi,et al.  Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies , 2001, Cancer.

[13]  S. Culine,et al.  Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  B. Monk,et al.  Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. , 1999, Gynecologic oncology.

[15]  D. Crivellari,et al.  Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. , 1997, European journal of cancer.

[16]  M. van Glabbeke,et al.  Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Winer,et al.  Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. , 1995, Seminars in oncology.

[18]  E. Vokes,et al.  Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Winer,et al.  Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Vokes,et al.  Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report. , 1994, Seminars in oncology.

[21]  J. Wagner.  Pharmacokinetics for the Pharmaceutical Scientist , 1993 .

[22]  R. Rahmani,et al.  Pharmacokinetics and metabolism of Navelbine. , 1989, Seminars in oncology.